Plus Therapeutics receives $3M award recommendation from U.S. DOD
The Fly

Plus Therapeutics receives $3M award recommendation from U.S. DOD

Plus Therapeutics announced it has been selected for funding by the Department of Defense office of the Congressionally Directed Medical Research Programs. The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer. “This recent award further extends our current cash runway in the second half of 2025, while supporting the 2024 expansion of our clinical development activities,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics. “In 2023, the Company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App